VENLO, the Netherlands, April 29, 2025--QIAGEN (NYSE: QGEN; Frankfurt Prime Standard: QIA) today announced the expansion of its cell and gene therapy (CGT) portfolio with an enhanced digital PCR ...

QIAcuity digital PCR kits, assays and protocols for lentivirus-based therapies support quality control in cell and gene therapy manufacturing Expansion underscores the commitment of QIAGEN to help ...

Lentiviral transduction is a popular and powerful gene delivery method for downstream applications such as cell line generation, therapeutic model generation and CAR-T research. However, current ...

AstraZeneca has entered the “off-the-shelf” cell therapy space, penning a $1 billion deal to acquire EsoBiotec and its lentiviral vector platform. The deal will see AstraZeneca scoop up all ...

In one of the largest private rounds raised by an Italian biotech, Genespire Srl has closed a €46.6 million (US$51.88 million) series B, enabling it to lay the ground for a phase I/II clinical trial ...

According to GlobalData’s Technology Foresights, which uses over 730,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the ...

The system consists of: (1) A clonal, suspension-adapted packaging cell line with stably-integrated lentiviral genes under inducible control, (2) Model-guided DNA design to optimize transgene ...

BOSTON, MA, USA and BERLIN, Germany, May 17, 2023 / B3C newswire / -- ProBioGen today announced the launch of their lentivirus (LV) packaging cell line Lenti.RiGHT™ as a new platinum standard for LV ...